Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer
| Autor: | Sierra A. Colavito, Zongzhi Liu, David F. Stern, Ryan Sokup, Matthew A. Held, James T. Platt |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Combination therapy CHK1 targeted drug combination screen epithelial-mesenchymal transition claudin-low breast cancer 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine Epithelial–mesenchymal transition CHEK1 B-cell lymphoma Triple-negative breast cancer 030304 developmental biology 0303 health sciences business.industry Cancer medicine.disease 3. Good health Regimen 030220 oncology & carcinogenesis triple-negative breast cancer business Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Sierra A. Colavito 1 , James T. Platt 2 , Matthew A. Held 3 , Zongzhi Liu 2 , Ryan Sokup 1 and David F. Stern 4 , 5 1 Department of Biology, University of Wisconsin-La Crosse, La Crosse, WI, USA 2 Department of Internal Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA 3 Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, USA 4 Department of Pathology, Yale School of Medicine, New Haven, CT, USA 5 Yale Cancer Center, New Haven, CT, USA Correspondence to: Sierra A. Colavito, email: scolavito@uwlax.edu Keywords: epithelial-mesenchymal transition; triple-negative breast cancer; targeted drug combination screen; claudin-low breast cancer; CHK1 Received: June 25, 2019 Accepted: July 05, 2019 Published: August 06, 2019 ABSTRACT Mesenchymal stem-like (MSL) breast cancers are enriched for cells with tumor reconstituting and mesenchymal characteristics. These cancers are often triple-negative and have a poor prognosis. Few effective targeted treatment options exist for patients with these cancers, and even when targeted therapies exist, resistance often arises and tumors recur, due in part to drug-tolerant persisting tumor cells with self-renewal capability. Effective treatment strategies will combine agents that target the bulk-tumor and reconstituting cells. In order to identify such a combination therapy, we conducted an inhibitor screen using 40 targeted agents at three different doses in all pairwise combinations. Checkpoint Kinase 1 (CHK1) inhibitors were identified as potent inhibitors of MSL breast cancers. When combined with a pro-apoptotic agent/B Cell Lymphoma 2 (BCL2) inhibitor, the effectiveness of the combination regimen was super-additive compared to either treatment alone and was selective for MSL cancers. Treatment of MSL breast cancer cells results in DNA damage, cell-cycle defects characterized by a prolonged S-phase, increased apoptosis and decreased colony forming abilities compared to untreated cells. These data suggest that a combination of a CHK1 and BCL2 inhibitor could be an effective treatment for patients with MSL breast cancer. Several other effective drug combinations were also identified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|